1/4 Very low
Study methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.By month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo.
Study findings. By month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo.
Comparison: Placebo